Elicera Therapeutics Ab Stock Cash Per Share
| ELIC Stock | 2.59 0.07 2.78% |
Elicera Therapeutics AB fundamentals help investors to digest information that contributes to Elicera Therapeutics' financial success or failures. It also enables traders to predict the movement of Elicera Stock. The fundamental analysis module provides a way to measure Elicera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elicera Therapeutics stock.
Elicera |
Elicera Therapeutics AB Company Cash Per Share Analysis
Elicera Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
| Competition |
In accordance with the recently published financial statements, Elicera Therapeutics AB has a Cash Per Share of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The cash per share for all Sweden stocks is 100.0% higher than that of the company.
Elicera Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elicera Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Elicera Therapeutics could also be used in its relative valuation, which is a method of valuing Elicera Therapeutics by comparing valuation metrics of similar companies.Elicera Therapeutics is currently under evaluation in cash per share category among its peers.
Elicera Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.23 | |||
| Operating Margin | (23.30) % | |||
| Current Valuation | 42.8 M | |||
| Shares Outstanding | 19.78 M | |||
| Shares Owned By Insiders | 62.87 % | |||
| Price To Book | 2.21 X | |||
| Price To Sales | 106.48 X | |||
| Revenue | 587 | |||
| Gross Profit | 587 | |||
| EBITDA | (13.11 M) | |||
| Net Income | (13.12 M) | |||
| Book Value Per Share | 1.85 X | |||
| Cash Flow From Operations | (14.29 M) | |||
| Earnings Per Share | (0.86) X | |||
| Market Capitalization | 78.53 M | |||
| Total Asset | 54.74 M | |||
| Net Asset | 54.74 M |
About Elicera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elicera Therapeutics AB's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elicera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elicera Therapeutics AB based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Elicera Stock Analysis
When running Elicera Therapeutics' price analysis, check to measure Elicera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Elicera Therapeutics is operating at the current time. Most of Elicera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Elicera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Elicera Therapeutics' price. Additionally, you may evaluate how the addition of Elicera Therapeutics to your portfolios can decrease your overall portfolio volatility.